I am a pediatric hematologist and oncologist with extensive experience in the use of cord blood transplants to treat babies, children, and young adults with leukemia, lymphoma, and other cancers and blood diseases.
Umbilical cord blood from healthy newborns is an excellent source of stem cells to rebuild a patient’s immune and blood systems. At Memorial Sloan Kettering, we try to present patients and their families with different treatment options, tailored to their individual situations. Cord blood has a number of advantages over blood or bone marrow from an unrelated donor. It is not necessary to find a perfect HLA (tissue type) match, making it particularly attractive for patients of ethnic minorities. Cord blood is more rapidly available, and there is a lower risk of a serious transplant complication called graft-versus-host disease, which occurs when the transplanted cells attack the normal tissues of the recipient’s body.
My colleagues and I have a great deal of experience in research that has led to cord blood transplantation being brought from the laboratory to the clinic. We are studying new ways to use cord blood to treat diseases of the blood and bone marrow. One approach we use is to increase the number of cord blood cells by combining two units from different donors (called “double-unit transplants”).
I have spoken nationally in support of cord blood transplantation to try to get more hospitals interested in participating in cord blood donation programs. I also teach fellows and give presentations at conferences about cord blood collection and its use in transplantation.
- Clinical Expertise: Pediatric Hematology and Oncology; Cord Blood Transplantation for Hematologic Disorders
- Languages Spoken: English
- Education: MD, University of Athens Medical School
- Residencies: Pediatrics - Massachusetts General Hospital/Harvard Medical School
- Fellowships: Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Pediatarics; Pediatric Hematology-Oncology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more